Interacciones de Cisplatino

Cisplatino (Platinol) tiene 21 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 6; moderadas: 7; leves: 8; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (6)

  • Fatal bleomycin pulmonary toxicity has been reported in a patient with unrecognized cisplatin-induced oliguric renal failure. (etiqueta de Bleomicina, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoGrave

    …magnesium hydroxide Prevention or Management: Phenytoin and antacids should not be taken at the same time of day Antineoplastic agents (usually in combination) Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other Chronic alcohol abuse, diazepam, diazoxide,… (etiqueta de Fenitoína, Interacciones medicamentosas)

  • GentamicinaaminoglucósidoGrave

    Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided (see PRECAUTIONS, Drug Interactions section). (etiqueta de Gentamicina, Advertencia en recuadro)

  • NeomicinaaminoglucósidoGrave

    Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (etiqueta de Neomicina, Advertencia en recuadro)

  • Pentamidinafármaco que prolonga el intervalo QTGrave

    Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (etiqueta de Pentamidina, Interacciones medicamentosas)

  • NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

Interacciones moderadas (7)

  • FosfenitoínaanticonvulsivoModerada

    …phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other Chronic alcohol abuse, diazepam, diazoxide,… (etiqueta de Fosfenitoína, Interacciones medicamentosas)

  • Furosemidadiurético de asaModerada

    • Cisplatin and nephrotoxic drugs : Risk of ototoxicity and nephrotoxicity ( 7.1 ) (etiqueta de Furosemida, Interacciones medicamentosas)

  • IfosfamidaModerada

    Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use. (etiqueta de Ifosfamida, Advertencias y precauciones)

  • RituximabinmunosupresorModerada

    Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. (etiqueta de Rituximab, Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etiqueta de Tacrolimus, Advertencias y precauciones)

  • TrilaciclibModerada

    Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e.g., dofetilide, dalfampridine, and cisplatin) [see Clinical Pharmacology ( 12.3 )]. (etiqueta de Trilaciclib, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. (etiqueta de Verapamilo, Interacciones medicamentosas)

Menciones leves (8)

  • Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Interacciones medicamentosas)

  • In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (etiqueta de Docetaxel, Advertencias y precauciones)

  • Espironolactonaantagonista de la aldosteronaLeve

    Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). (etiqueta de Espironolactona, Advertencias y precauciones)

  • Cisplatin may affect melphalan kinetics by inducing renal dysfunction and subsequently altering melphalan clearance. (etiqueta de Melfalán, Interacciones medicamentosas)

  • Ondansetrónfármaco que prolonga el intervalo QTLeve

    Chemotherapy In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. (etiqueta de Ondansetrón, Interacciones medicamentosas)

  • PemetrexedantimetabolitoLeve

    …(38% versus 23%), thrombocytopenia (9% versus 5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received pemetrexed plus cisplatin without vitamin supplementation as compared to patients who were fully supplemented with folic acid and vitamin B 12 prior to and throughout pemetrexed plus cisplatin treatment. (etiqueta de Pemetrexed, Advertencias y precauciones)

  • Torasemidadiurético de asaLeve

    Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). (etiqueta de Torasemida, Advertencias y precauciones)

  • Myelosuppression Myelosuppression, manifested by neutropenia, anemia and thrombocytopenia, occur in patients receiving vinorelbine as a single agent and in combination with cisplatin [see Adverse Reactions ( 6.1 , 6.2 )] . (etiqueta de Vinorelbina, Advertencias y precauciones)

Compruebe Cisplatino frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.